CYCN: Engineering a reset; initiating coverage of Cyclerion Therapeutics
- Posted on February 2, 2026
- By Bing News
- 1 Views
CYCN: Engineering a reset; initiating coverage of Cyclerion Therapeutics
By David Bautz, PhD NASDAQ:CYCN READ THE FULL CYCN RESEARCH REPORT Initiating Coverage We are initiating coverage of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) with a valuation of $8.00. Cyclerion is a clinical-stage biopharmaceutical company that has recently undergone a strategic transformation to focus on the development of novel neuropsychiatric therapies, with an initial emphasis on treatment-resistant depression (TRD). Cyclerion’s lead... continue reading...
